Skip to main content
OpenTrials
Completed

NCT Number: NCT07722000

Different Treatment Options Used for Post Covid-19 Syndrome

This study aimed to assess functioning during the recovery phase post-COVID-19 and to evaluate symptoms prolonging after COVID-19 infection and how to manage these symptoms.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID-19 Chronic Disease Coronaviridae Infections Coronavirus Infections Disease Attributes Ginkgo Biloba Infections Lung Diseases Nidovirales Infections Pathologic Processes Pathological Conditions, Signs and Symptoms Piracetam Pneumonia Pneumonia, Viral Post COVID-19 Syndrome Post-Acute COVID-19 Syndrome Post-Infectious Disorders RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Beni Suef University

Banī Suwayf, Beni Suweif Governorate, 62511, Egypt

About this study

COVID-19 is a disease caused by a new strain of coronavirus The COVID-19 virus is a new virus linked to the same family of viruses as severe acute respiratory syndrome (SARS) and some types of common cold. Symptoms can include fever, cough, and shortness of breath. In more severe cases, infection can cause pneumonia or breathing difficulties. More rarely, the disease can be fatal. These symptoms are similar to the flu (influenza) or the common cold, which are a lot more common than COVID-19.

The virus is transmitted through direct contact with respiratory droplets of an infected person (generated through coughing and sneezing). Individuals can also be infected from and touching surfaces contaminated with the virus and touching their face (e.g., eyes, nose, mouth).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged from 18 to 70 years.
  • Both sexes.
  • Positive diagnosis of COVID-19 within the last 3 months in relation to the time of assessment (COVID-19 diagnosis had been previously confirmed by RT-PCR nasal swab testing as part of routine clinical evaluation before enrollment into the study).

Exclusion criteria

  • Patients with other non-COVID-related chronic illnesses that could interfere with the assessment of post-viral symptoms.
  • Patients with pre-existing neurological disorders that could affect cognitive function or fatigue assessment, including dementia, Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, or prior cerebrovascular stroke, patients with diagnosed psychiatric disorders such as major depressive disorder, bipolar disorder, schizophrenia, or anxiety disorders requiring ongoing pharmacological treatment.
  • Patients with uncontrolled endocrine disorders, particularly uncontrolled diabetes mellitus or thyroid dysfunction.
  • Patients with malignancy or receiving chemotherapy, radiotherapy, or immunosuppressive therapy during the study period.
  • Patients with chronic fatigue syndrome, fibromyalgia, or other pre-existing fatigue-related disorders diagnosed prior to SARS-CoV-2 infection.
  • Patients with substance abuse or alcohol dependence, pregnant or lactating women.
  • Patients with known hypersensitivity or contraindications to Ginkgo biloba or piracetam.
  • Patients with poor adherence to treatment or anticipated inability to complete follow-up visits.

Treatment and study plan

Ginkgo biloba

Drug

Patients who received Ginkgo biloba alone.

piracetam

Drug

Patients who received piracetam alone.

Ginkgo biloba and Piracetam

Drug

Patients who received a combination (Ginkgo biloba and Piracetam).

Primary outcomes

  1. Mini-Mental State Examination (MMSE)

    Time frame: 1 year after the procedure

    The Mini-Mental State Examination (MMSE) was used to assess global cognitive status. It evaluates orientation, immediate and delayed recall, attention and calculation, language, and visuospatial construction. The total score ranges from 0 to 30, with higher scores reflecting better cognitive function. Cognitive impairment was classified as mild (21-24), moderate (10-20), or severe (<10). The MMSE was administered in a face-to-face interview format

Secondary outcomes

  1. Fatigue Severity Scale

    Time frame: 1 year after the procedure

    Fatigue Severity Scale (FSS) is a validated, widely used self-report instrument designed to quantify the severity and impact of fatigue on daily functioning over the previous seven days. It consists of nine statements covering aspects such as motivation, exercise-induced fatigue, physical functioning, and interference with work, social, and family life. For each item, patients rate their level of agreement on a 7-point scale where 1 indicates strong disagreement and 7 indicates strong agreement. Higher scores on the nine item values (ranging from 1.0 to 7.0) indicate more severe fatigue, with a mean score of 4.0 or higher considered indicative of moderate to severe fatigue. Sum score: total of all item values (9-63). Mean score: average of the 9 item values (1.0-7.0)

  2. Changes in headache severity

    Time frame: 1 year after the procedure

    Headache by visual analogue scale (VAS) was recorded was recorded at baseline, after 3 months, 6 months, and after 1 year. Pain was assessed by using visual analogue scale (VAS) which is presented as a 10 cm straight line reflecting the extremes of "no pain" and "worst pain. All patients included were followed longitudinally after initiation of treatment, with scheduled follow-up visits for 3 months, 6 months, and 12 months to assess persistence, improvement, or resolution of symptoms.

  3. Prevalence of neurological manifestations

    Time frame: 1 year post-procedure

    Prevalence of neurological manifestations related to post-COVID syndrome were recorded.

Sponsors and collaborators

Lead sponsor

Beni-Suef University

Other

Registry information

Official study title

Evaluation of Different Treatment Options Used for Post Covid-19 Syndrome

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Jul 23, 2026
Registry last updated
Jul 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.